SCHEDULE 13G/A: Federated Hermes and Donahue Family Disclose 17.47% Stake in ATYR Pharma

Federated Hermes, Inc., along with the Donahue family and related trusts, has disclosed a beneficial ownership of 17.47% of ATYR Pharma, Inc.'s common stock as of December 31, 2024.

Summary

• Federated Hermes, Inc., a Pennsylvania-based parent holding company, has filed an Amendment No. 9 to Schedule 13G, disclosing its beneficial ownership in ATYR Pharma, Inc.
• As of December 31, 2024, Federated Hermes, Inc. and its affiliated entities, including the Voting Shares Irrevocable Trust and its trustees (Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue), collectively beneficially own 14,666,600 shares of ATYR Pharma, Inc. common stock.
• This aggregate amount represents 17.47% of the total outstanding common stock of ATYR Pharma, Inc.
• Federated Hermes, Inc. and the Voting Shares Irrevocable Trust each hold sole voting power and sole dispositive power over 14,666,600 shares.
• The individual Donahue trustees (Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue) each hold shared voting power and shared dispositive power over 14,666,600 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a substantial beneficial ownership stake by a major investment firm like Federated Hermes, Inc. and related entities generally signals confidence in the issuer, ATYR Pharma, Inc., from a significant institutional investor perspective. This is a positive signal, though the filing itself is a routine disclosure.

Positives

• The disclosure of a significant beneficial ownership stake by a major institutional investor like Federated Hermes, Inc. can signal confidence in ATYR Pharma, Inc.'s long-term prospects.
• Increased institutional ownership often suggests a thorough due diligence process has been conducted, potentially validating the company's strategy or valuation.

Future Outlook

NA

Industry Context

Schedule 13G filings are routine disclosures by passive institutional investors or groups that acquire more than 5% of a company's voting stock. Such filings provide transparency into significant ownership stakes, which can influence market perception and investor sentiment. For a biotechnology company like ATYR Pharma, Inc., a substantial stake held by a large asset manager like Federated Hermes, Inc. can be interpreted as a vote of confidence in its pipeline or strategic direction, potentially attracting further investor interest.

Stakeholder Impact

• Shareholders may view the significant institutional ownership as a positive indicator of investor confidence and stability.
• The disclosure provides transparency to the market regarding the ownership structure of ATYR Pharma, Inc.

Key Dates

Recommendation

Keywords

ATYR Pharma, Federated Hermes, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals, SEC Filing